FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549404313> ?p ?o ?g. }

• W2549404313 endingPage "131" @default.
• W2549404313 startingPage "125" @default.
• W2549404313 abstract "Achieving consistent protection by vaccinating pigs against porcine reproductive and respiratory syndrome virus (PRRSV) remains difficult. Recently, an interferon-inducing PRRSV vaccine candidate strain A2MC2 was demonstrated to be attenuated and induced neutralizing antibodies. The objective of this study was to determine the efficacy of passage 90 of A2MC2 (A2P90) to protect pigs against challenge with moderately virulent PRRSV strain VR-2385 (92.3% nucleic acid identity with A2MC2) and highly virulent atypical PRRSV MN184 (84.5% nucleic acid identity with A2MC2). Forty 3-week old pigs were randomly assigned to five groups including a NEG-CONTROL group (non-vaccinated, non-challenged), VAC-VR2385 (vaccinated, challenged with strain VR-2385), VR2385 (challenged with strain VR-2385), VAC-MN184 (vaccinated, challenged with strain MN184) and a MN184 group (challenged with MN184 virus). Vaccination was done at 3 weeks of age followed by challenge at 8 weeks of age. No viremia was detectable in any of the vaccinated pigs; however, by the time of challenge, 15/16 vaccinated pigs had seroconverted based on ELISA and had neutralizing antibodies against a homologous strain with titers ranging from 8 to 128. Infection with VR-2385 resulted in mild-to-moderate clinical disease and lesions. For VR-2385 infected pigs, vaccination significantly lowered PRRSV viremia and nasal shedding by 9 days post challenge (dpc), significantly reduced macroscopic lung lesions, and significantly increased the average daily weight gain compared to the non-vaccinated pigs. Infection with MN184 resulted in moderate-to-severe clinical disease and lesions regardless of vaccination status; however, vaccinated pigs had significantly less nasal shedding by dpc 5 compared to non-vaccinated pigs. Under the study conditions, the A2P90 vaccine strain was attenuated without detectable shedding, improved weight gain, and offered protection to the pigs challenged with VR-2385 by reduction of virus load and macroscopic lung lesions. Further work is needed to investigate different vaccination and challenge protocols, including routes, doses, timing and strains." @default.
• W2549404313 created "2016-11-30" @default.
• W2549404313 creator A5022361895 @default.
• W2549404313 creator A5027162909 @default.
• W2549404313 creator A5028659991 @default.
• W2549404313 creator A5073143506 @default.
• W2549404313 creator A5076424727 @default.
• W2549404313 creator A5077161767 @default.
• W2549404313 creator A5083578498 @default.
• W2549404313 date "2017-01-01" @default.
• W2549404313 modified "2023-10-17" @default.
• W2549404313 title "An interferon inducing porcine reproductive and respiratory syndrome virus vaccine candidate elicits protection against challenge with the heterologous virulent type 2 strain VR-2385 in pigs" @default.
• W2549404313 cites W1505653987 @default.
• W2549404313 cites W1964271390 @default.
• W2549404313 cites W1964942316 @default.
• W2549404313 cites W1967848191 @default.
• W2549404313 cites W1993299212 @default.
• W2549404313 cites W1998128231 @default.
• W2549404313 cites W2000742077 @default.
• W2549404313 cites W2004448581 @default.
• W2549404313 cites W2014070304 @default.
• W2549404313 cites W2014500763 @default.
• W2549404313 cites W2015544673 @default.
• W2549404313 cites W2015721404 @default.
• W2549404313 cites W2021751941 @default.
• W2549404313 cites W2022506220 @default.
• W2549404313 cites W2027609520 @default.
• W2549404313 cites W2036951693 @default.
• W2549404313 cites W2051013202 @default.
• W2549404313 cites W206556109 @default.
• W2549404313 cites W2069016864 @default.
• W2549404313 cites W2100160011 @default.
• W2549404313 cites W2107300216 @default.
• W2549404313 cites W2140296277 @default.
• W2549404313 cites W2162790707 @default.
• W2549404313 cites W2169128111 @default.
• W2549404313 cites W2547976151 @default.
• W2549404313 cites W755303132 @default.
• W2549404313 doi "https://doi.org/10.1016/j.vaccine.2016.11.020" @default.
• W2549404313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27876202" @default.
• W2549404313 hasPublicationYear "2017" @default.
• W2549404313 type Work @default.
• W2549404313 sameAs 2549404313 @default.
• W2549404313 citedByCount "9" @default.
• W2549404313 countsByYear W25494043132017 @default.
• W2549404313 countsByYear W25494043132018 @default.
• W2549404313 countsByYear W25494043132020 @default.
• W2549404313 countsByYear W25494043132021 @default.
• W2549404313 countsByYear W25494043132022 @default.
• W2549404313 countsByYear W25494043132023 @default.
• W2549404313 crossrefType "journal-article" @default.
• W2549404313 hasAuthorship W2549404313A5022361895 @default.
• W2549404313 hasAuthorship W2549404313A5027162909 @default.
• W2549404313 hasAuthorship W2549404313A5028659991 @default.
• W2549404313 hasAuthorship W2549404313A5073143506 @default.
• W2549404313 hasAuthorship W2549404313A5076424727 @default.
• W2549404313 hasAuthorship W2549404313A5077161767 @default.
• W2549404313 hasAuthorship W2549404313A5083578498 @default.
• W2549404313 hasBestOaLocation W25494043132 @default.
• W2549404313 hasConcept C104317684 @default.
• W2549404313 hasConcept C12914427 @default.
• W2549404313 hasConcept C159047783 @default.
• W2549404313 hasConcept C203014093 @default.
• W2549404313 hasConcept C22070199 @default.
• W2549404313 hasConcept C2522874641 @default.
• W2549404313 hasConcept C2776185481 @default.
• W2549404313 hasConcept C2779261636 @default.
• W2549404313 hasConcept C2779819720 @default.
• W2549404313 hasConcept C32611913 @default.
• W2549404313 hasConcept C55493867 @default.
• W2549404313 hasConcept C60987743 @default.
• W2549404313 hasConcept C71924100 @default.
• W2549404313 hasConcept C86803240 @default.
• W2549404313 hasConceptScore W2549404313C104317684 @default.
• W2549404313 hasConceptScore W2549404313C12914427 @default.
• W2549404313 hasConceptScore W2549404313C159047783 @default.
• W2549404313 hasConceptScore W2549404313C203014093 @default.
• W2549404313 hasConceptScore W2549404313C22070199 @default.
• W2549404313 hasConceptScore W2549404313C2522874641 @default.
• W2549404313 hasConceptScore W2549404313C2776185481 @default.
• W2549404313 hasConceptScore W2549404313C2779261636 @default.
• W2549404313 hasConceptScore W2549404313C2779819720 @default.
• W2549404313 hasConceptScore W2549404313C32611913 @default.
• W2549404313 hasConceptScore W2549404313C55493867 @default.
• W2549404313 hasConceptScore W2549404313C60987743 @default.
• W2549404313 hasConceptScore W2549404313C71924100 @default.
• W2549404313 hasConceptScore W2549404313C86803240 @default.
• W2549404313 hasIssue "1" @default.
• W2549404313 hasLocation W25494043131 @default.
• W2549404313 hasLocation W25494043132 @default.
• W2549404313 hasLocation W25494043133 @default.
• W2549404313 hasLocation W25494043134 @default.
• W2549404313 hasLocation W25494043135 @default.
• W2549404313 hasOpenAccess W2549404313 @default.
• W2549404313 hasPrimaryLocation W25494043131 @default.
• W2549404313 hasRelatedWork W1865665459 @default.
• W2549404313 hasRelatedWork W1933588764 @default.
• W2549404313 hasRelatedWork W2036951693 @default.

• next